Since all general anaesthetics induce unconsciousness, one might imagine they broadly act similarly such that two anaesthetics together are more, not less, powerful than one alone. In terms of minimum alveolar concentration (MAC) this notion is expressed as: 'MACs are additive' [1] . If the MAC of sevoflurane is~2.2% and that of N 2 Õ 100%, then adding 50% N 2 O to 2.2% sevoflurane results in a 'dose' of~1.5 MAC; i.e. N 2 O enhances the action of sevoflurane, it does not wake the patient up. If the combined 'dose' were > 1.5 MAC, this is 'synergistic' or 'multiplicative'; anything < 1.5 MAC is 'infra-additive', 'subtractive' or 'antagonistic'. Additive (or occasionally synergistic) interactions between anaesthetic pairs are the norm, but infra-additivity is not well described and difficult to explain within the current paradigm of mechanisms of anaesthetic action [2] [3] [4] [5] [6] .
In this issue of the journal, Niu et al. provide evidence challenging the notion of universal additivity/ synergy in anaesthetic combinations [7] . They report that N 2 O antagonises sevoflurane's ability to produce an iso-electric EEG. Is N 2 O waking the patient up? Before we turn to this question, we will first discuss the place of 'additivity' in current understanding of anaesthetic mechanisms.
Current interpretation of anaesthetic interactions
In an important set of papers published in a single issue of Anesthesia and Analgesia [2] [3] [4] [5] [6] , a large, multicentre team of distinguished researchers addressed two key questions: (1) do anaesthetics generally interact additively, synergistically or infra-additively? (2) how are each of these interactions to be interpreted?
The authors supplemented a comprehensive literature review with direct studies at whole-body (macro-) level in animals, and at cellular/molecular (micro-) level on ligand-gated receptors. For simplicity, I refer to the collected papers [2] [3] [4] [5] [6] as 'Shafer et al.' after that journal's then Editor-in-Chief, who was also a co-author.
In answer to the first question, Shafer et al. confirmed that interactions of inhaled agents always appeared additive (except for one possible infra-additive interaction between isoflurane and N 2 O). They confirmed that intravenous agents acting predominantly at the same receptor (e.g. propofol and thiopental at GABA-A) also interacted additively. However, combinations of intravenous agents acting predominantly at different receptors, or those whose mechanisms were unknown, could interact synergistically. They reported some infrequent infra-additive interactions between ketamine and some other agents.
Shafer et al. interpreted an additive effect at macro-level (i.e. additive MACs) as consistent with a unitary mechanism of action. These agents could be regarded as acting via a common pathway to achieve the same maximum effect; i.e. similar efficacy but different potencies [2] [3] [4] [5] [6] . The unitary model could be a receptor or non-receptor mechanism, such as the 'lipid hypothesis', where anaesthetics are purported to work by dissolving in and then expanding the membrane to a critical point that triggers the key changes to induce anaesthesia (e.g. the Overton-Meyer hypothesis) [8] .
Shafer et al. argued that synergistic interactions imply more complex molecular mechanisms involving multiple receptors or pathways, with some pathways able to leverage the activities of others, producing a greater-than-additive effect [2] [3] [4] [5] [6] produced only additive or synergistic effects [9] . Infra-additive interactions occurred too infrequently in their studies for Shafer et al. to offer an explanation [2] [3] [4] [5] [6] ; i.e. they could not explain how an agent that itself was anaesthetic could actually lessen the effect of another anaesthetic agent.
The bulk of Shafer et al.'s work was focussed on the macro-level, whole-body effect of agents on MAC [3] [4] [5] , with subsequent theoretical analyses of what these responses might imply at molecular level [2] , and in a parallel paper examining the electrophysiology of three isolated ligand-gated channels (NMDA, GABA-A, glycine), they confirmed only additive interactions [2] (notably, however, ketamine and N 2 O were not examined).
The possibility of infraadditive effects in anaesthetic combinations
At macro-level, infra-additive interactions might arise from physiological antagonism [10] . It is possible for a generally stimulant, nonanaesthetic drug to reverse the depressive actions of an anaesthetic, by making the brain globally more active (e.g. metabolically) and so less receptive to any inhibitory effects [11] .
A review article by Little [10] did not entertain the possibility of anaesthetic mixtures being mutually infra-additive, but such observations have been made in occasional reports over the years. At macrolevel, DiFazio et al. (1972) reported in mice (response to tail clamp) that mixtures of cyclopropane with N 2 O or ethylene were infra-additive [12] . The lipid theory was then the prevailing paradigm, and they proposed that these agents competed for the same hypothetical hydrate site in the plasma membrane. Intriguingly, this concept comes close to the modern notion of competition at a single 'receptor' (albeit in their suggestion a non-proteinaceous one). Clarke et al. (1978) found argon and sulphur hexafluoride were infra-additive in mice, but additive in newts. They ascribed the unusual antagonism as experimental error or species-specific [13] .
In humans at macro-level, N 2 O has been reported to reduce -not increase -self-reported feelings of sleepiness with low dose sevoflurane; while in turn sevoflurane antagonised the analgesic effects of N 2 O [14] . Interestingly, Janiszewski et al. [14] found that the two agents were additive in their depressive effects on psychomotor performance, suggesting that agents can be differently additive, synergistic or infra-additive on different macro-endpoints.
Reports of mutual antagonism at micro-level, on the activity of channels or receptors have been sparse, but do exist. At this level, pharmacological antagonism must be at play (i.e. direct competition between agents at a single receptor).
Hadipour-Jahromy and Daniels studied a1 glycine receptors expressed in Xenopus oocytes, where methohexitone had no influence itself on channel function, but it antagonised thiopental, pentobarbitone and propofol (i.e. pure antagonist) [15] . Beckstead et al. took this forward. In the same experimental model, they first confirmed that enflurane, toluene, chloroform and ethanol activated glycine channel function. Then, they constructed a mutant glycine channel specifically ethanol-insensitive. In this mutant channel, ethanol antagonised the other agents, confirming competition at a common binding site [16] . While both these studies were dramatic as proof-of-principle that an anaesthetic (methohexital [15] and ethanol [16] , respectively) could antagonise the actions of other anaesthetics at a single receptor, the drawback was that neither study employed a relevant biological model. Methohexitone is decidedly a potent anaesthetic, so if it had no effect on the a1-glycine receptor in Hadipour-Jahromy and Daniels' study [15] , then this was by definition not a meaningful construct for general anaesthesia. Similarly, by mutating the channel, Beckstead et al. [16] merely created an artificial construct in which ethanol was no longer the anaesthetic it normally is in the native preparation.
Against this background of sporadic 'infra-additive' reports in unusual experimental settings, the results of Niu et al. [7] are important for several reasons. First, their study was in humans. Second, it is possibly the first infra-additive result at meso-level (i.e. at the level of brain networks, reflected in EEG patterns). All previous studies of anaesthetic mixtures appear to have been at macro-or micro-level. Third, in common with Janiszewski et al. [14] , they have demonstrated potentiation between the agents on some parameters (EEG burst suppression) while showing antagonism on others (isolectric EEG).
Physiological antagonism
If reproducible, this would be a truly remarkable observation: that one anaesthestic is able to antagonise the effect of another. Shafer et al. could not articulate a model in which this could arise, but suggestions can be offered.
One possibility is that physiological antagonism could underlie the infra-additive results. If so, this implies that different anaesthetics can act on diverse, opposing pathways within a brain network. Since each pathway is mediated by its own unique set of molecular receptors [17] , this in turn means that each anaesthetic agent must be acting via its own distinct family of receptors, rather than by any common, non-specific or unitary molecular mechanism [18, 19] . Therefore, in the same way as synergy more strongly supports a non-unitary mechanism than a unitary one, as argued by Shafer et al. [2] [3] [4] [5] [6] , so too does a finding of infra-additivity, if physiological antagonism underlies it. Niu et al.'s result could suggest that the pathway (and hence receptor group) mediating burst suppression is different from that mediating an iso-electric EEG.
Pharmacological antagonism
A different, and more radical, possibility is that pharmacological antagonism between sevoflurane and N 2 O underlies the infra-additivity in Niu et al.'s study. Whether different agents compete at a receptor could be tested experimentally. All that is needed is to administer binary combinations of agents in accurate concentrations [20] Opposing actions of agents are indeed seen in several receptors that have putative function, and these would be prime candidates to test the theory of pharmacological antagonism. Whereas halothane opens background K+ channels (TASK-1) [21] [22] [23] , both chloroform [24] and isoflurane close them [25] . Halothane and isoflurane potentiate 5-HT3 (5-hydroxytryptamine type 3)-induced receptor currents, whereas sevoflurane and N 2 O inhibit these [26] . Several other opposing effects of agents on receptors are summarised in a table presented by Rudolph and Antkowiak [17] . Yet, remarkably, combinations of these agents at these channels do not appear to have been tested for infra-additivity in a systematic way. These experiments now seem imperative.
Partial agonism by an anaesthetic would in theory accommodate the fact that the agent was itself an anaesthetic, whilst also explaining how it was antagonistic in combination. The clinical anaesthetic effect would arise at presumably relatively low receptor occupancy (Fig. 1a) [27, 28] . One reason why partial agonist behaviour may have been missed is that it requires relatively high (supraclinical) concentrations to detect it, through a full 'dose-response' curve ( Fig. 1) [30] . Generally, researchers are encouraged by reviewers and peer pressure to study only 'clinically relevant' concentrations [31] . Fig. 1b shows why, in experiments confined to low concentrations, partial agonism is impossible to demonstrate. Indeed, combining a partial agonist with a low dose of full agonist results in a misleadingly 'additive' effect [27] [28] [29] . Interestingly, Niu et al. report antagonistic effects only for iso-electric EEG, a state achieved by higher-thannormal anaesthetic concentrations.
Sincoff et al. have reported that halothane can behave as a partial agonist at a GABA receptor with an a6-subtype expressed in HEK cells [32] . However, these receptors may not be anaesthetically relevant, as they constitute < 10% of GABA subtypes, are found almost exclusively in cerebellar granule cells and classed as 'benzodiazepine-insensitive'. Similar partial agonist behaviour for halothane has been reported for a subunit of an inwardly rectifying K+ channel [33] and Jonsson Fagerlund et al. describe propofol as a partial agonist at the a2b2c2 GABA-A receptor [34] . Nitrous oxide can be regarded as a partial agonist, as its MAC is > 100%, so it never reaches its full efficacy for consciousness or for analgesic properties (the latter action exerted via opiate receptors) [35] . Notwithstanding Niu et al.'s study was in a population of patients and not measurement of single receptor activity, the similarity of their Fig. 4B and Fig. 1b in this editorial (characteristic of partial agonism) is striking.
Relevant infra-additive interactions can arise at receptors not normally regarded as primary targets for anaesthetics. Recently, Bojak et al. argued that the different EEG patterns evoked by ketamine and propofol were not simply due to their different putative primary receptor targets (NMDA and GABA, respectively). They modelled data from mixtures of the drugs and concluded that typical EEG patterns resulting arose from infra-additivity at a 'secondary receptor', HCN (hyperpolarisationactivated cyclic nucleotide-gated) channels, with ketamine being the partial agonist [36] .
Conclusions
In science, it is the exceptions that matter. It is irrelevant that there are many more observations favouring a flat earth than there are for a round one, or for a geocentric vs. heliocentric solar system, or for additivity/synergy vs. antagonism. What matters is that, in each case, the contrary result cannot be wholly accommodated within the respective existing paradigms. Thus, the prevailing hypothesis needs modifying. Perhaps the results of Niu et al. are not themselves enough, but they add to a growing number of observations suggesting that when anaesthetics collide, infra-additivity can result. If mimicked at receptor level (and this remains a big 'if'), this can only be explained by pharmacological antagonism between some anaesthetic agents. This does not preclude additive/synergistic interactions Idealised response-concentration relationships (log scale) at the receptor for the full agonist A (black line) and this time for the combination of a large, fixed concentration of partial agonist B with an increasing concentration (read off x-axis) of the full agonist A (red line). At low, clinically-relevant concentrations of A, the effect of high concentration B dominates, giving the appearance of enhancing effect of A alone (the range marked by arrow). At supra-clinical concentrations, the antagonistic behaviour of B becomes apparent. Both panels are based on standard modelling of agonist-partial agonist combinations as described, for example in references [28] [29] [30] .
at other receptors; but it does require a new general model for anaesthetic action at receptor level.
All this should cause us to study binary combinations of anaesthetics much more diligently than hitherto, especially examining concentrations greatly exceeding the conventional 'clinically relevant range'. If an anaesthetic combination were ever found, that mimicked the green line in Fig. 1 for a biologically relevant receptor, it would be a truly astonishing and extraordinary result, worthy then of some paradigm shift. The search should be on. So far, so pharmacologically exciting -but is any of this clinically interesting? Even if an anaesthetic is shown to be a partial agonist, or even if an anaesthetic combination is found to be mutually antagonistic, what practical use could that knowledge possibly have?
